Notably, while miR-125b has been shown to upregulate signaling pathways that are commonly activated in numerous cancers, such as Wnt/β-catenin and PI3K/AKT49 miR-125b has also been shown to suppress the progression of Ewing’s sarcoma, bladder cancer, gastric cancer, cervical cancer, thyroid cancer, and NSCLC via PI3K/AKT signaling pathways35,62–66. This evidence concerns the gene PIK3CB and urinary bladder carcinoma.